P roliferation of vascular smooth muscle cells (VSMCs) is a central axiom of most models of atherosclerosis, promoting atherogenesis as a response to injury 1 or inflammation. 2 However, most heart attacks are caused by rupture of a "vulnerable" plaque with a thin VSMC-poor fibrous cap overlying a relatively large necrotic core. 3,4 Plaque repair requires VSMC proliferation and is thus beneficial at this stage. However, VSMCs from advanced human plaques show poor proliferation and premature senescence in culture 5 and in vivo 6 ; furthermore, fibrous cap VSMCs show extensive DNA damage, marked telomere shortening, and markers of senescence. 7 Although these findings suggest that VSMC senescence may be important in atherogenesis, its mechanisms and direct consequences are unproven.
P roliferation of vascular smooth muscle cells (VSMCs) is a central axiom of most models of atherosclerosis, promoting atherogenesis as a response to injury 1 or inflammation. 2 However, most heart attacks are caused by rupture of a "vulnerable" plaque with a thin VSMC-poor fibrous cap overlying a relatively large necrotic core. 3, 4 Plaque repair requires VSMC proliferation and is thus beneficial at this stage. However, VSMCs from advanced human plaques show poor proliferation and premature senescence in culture 5 and in vivo 6 ; furthermore, fibrous cap VSMCs show extensive DNA damage, marked telomere shortening, and markers of senescence. 7 Although these findings suggest that VSMC senescence may be important in atherogenesis, its mechanisms and direct consequences are unproven.
We examined the expression of proteins that protect telomeres in human VSMCs derived from atherosclerotic plaques or normal arteries. We demonstrate that plaque VSMCs show reduced expression and telomere binding of TRF2, associated with increased markers of DNA damage. Gain-and loss-of-function studies of TRF2 in apolipoprotein (Apo)E -/-mice show that VSMC senescence regulates both plaque development and morphology. We conclude that plaque VSMC senescence in atherosclerosis is regulated by TRF2 and promotes both atherosclerosis and features of plaque vulnerability.
Methods

Human Atherosclerotic Plaque and Normal Vessels
Plaques and normal aortas were obtained from patients undergoing carotid endarterectomy or coronary artery bypass/valve replacement, respectively, under informed consent using protocols approved by the Cambridge or Huntingdon Research Ethical Committee. Age-and sex-matched human normal aortas and carotid plaque VSMCs were cultured from tissue explants and studied at passages 2 to 5; VSMC cultures from individual patients were not pooled. Cells were cultured in DMEM containing 20% FCS supplemented with 100 U/mL of penicillin, 100 μg/mL of streptomycin, and 2 mmol/L l-glutamine.
Protein Extraction and Western Blotting
Protein extraction from cultured cells and Western blotting were performed as described previously 20 and in the online-only Data Supplement Methods section.
Chromatin Immunoprecipitation
TRF2 association with telomeres was examined by chromatin immunoprecipitation as described previously 21 and in the online-only Data Supplement Methods section.
Immunocytochemistry
Immunocytochemistry for nuclear foci was performed as described previously 20 and in the online-only Data Supplement Methods section.
Immunohistochemistry
Immunohistochemistry of human and mouse arteries was performed as described previously.
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Plasmid Constructs cDNAs of human TRF2, TRF2 ΔB (lacking N-terminal basic domain), TRF2
ΔM (lacking C-terminal Myb domain), and TRF2 ΔBΔM (lacking both basic and Myb domains) in retrovirus pWZL-hygro-nMyc vectors were purchased from Addgene (Cambridge, MA; originally supplied by Dr Titia de Lange, Rockefeller University, New York, NY). cDNAs from human TRF2 T188A (constitutively unphosphorylated at T188) and TRF2 T188E (constitutively phosphorylated) in the pTET vector were kind gifts from Dr David Gilley (Jasper, IN) and were subsequently subcloned into the pWZL-hygro-nMyc vector.
Generation of Stable Cell Lines
All of the cDNAs cloned into retrovirus pWZL-hygro-nMyc vectors (TRF2, TRF2 ΔB , TRF2 ΔM , TRF2 ΔBΔM , TRF2  T188A , and TRF2  T188E ) or the empty vector were transfected into Bosc23 ecotropic packaging cells using HiPerfect transfection agent (Invitrogen, Carlsbad, CA). Replication-deficient virus was used to infect mouse ApoE -/-VSMCs. Infected cells were selected with 250µg/mL of hygromycin (Roche, Basel, Switzerland) and TRF2 expression confirmed by Western blot.
Cell Culture
Mouse cell lines were cultured as described in the online-only Data Supplement Methods section.
Time Lapse Videomicroscopy
Cells were cultured overnight in 6-well plates at 3×10 4 cells per well. Cells were incubated in 40 µm HEPES (pH 7.2) for 1 hour before recording using OpenLAB software (Agilent Technologies, Santa Clara, CA), taking 3 image frames per well using a time-lapse BX51 microscope (Olympus Corporation, Tokyo, Japan), air-cooled CCD camera (CoolSNAP, Photometrics, Tucson, AZ), and imaging and analysis software (Soft Imaging System, Berlin, Germany). More than 100 cells per cell line were analyzed and cell proliferation and apoptosis assayed. Not-dividing was defined as no observed divisions over 48 hours (approximately 4 cycles).
Senescence-Associated β-Galactosidase
Detection of senescence-associated β-galactosidase was as described previously.
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Comet Assay
A total of 10 5 cells were washed in PBS, resuspended in 150 µL of 1% low melting point agarose/PBS and left to cool on Gelbond plastic films (Lonza Group, Basel, Switzerland) at 4°C for 10 minutes. After immersing in lysis buffer (2.5 mol/L of NaCl; 100 mmol/L EDTA; 10 mmol/L Trizma base; pH 10) overnight at 4°C, gel films were transferred into electrophoresis buffer (0.3 mol/L of NaOH; 1 mmol/L EDTA; pH >13) for 30 minutes before electrophoresis at 24 V and 300 mA for 30 minutes at 4°C. Gel films were washed 3 times in neutralization buffer (0.4 mol/L of Tris; pH 7.5), once in distilled H 2 O, and incubated in ice-cold ethanol for 10 minutes. Films were dried overnight, rehydrated in distilled H 2 O for 10 minutes, and stained with 2 µg/mL of ethidium bromide (Sigma Aldrich, St Louis, MO) in the dark at room temperature for 2 hours. Multiple images per slide were analyzed using a Zeiss microscope and comet tail length/ moment measured using Comet Assay IV software (Perception Instruments, UK).
Experimental Animals
All of the animal procedures followed United Kingdom Home Office licensing and were approved by the local animal ethical committee. To produce constructs for transgenesis, hemagglutinin tags were inserted at the N-terminus of TRF2 and TRF2 T188A cDNA by enzymatic reaction. Tagged cDNAs were subcloned between the minimal SM22α promoter 23 and polyA sequence in a pBS vector. Transgenic mice expressing SM22α-TRF2 or -TRF2
T188A were generated by pronuclear injection. Founders were bred to ensure transgene transmission and expression and then backcrossed 5 times with ApoE -/-mice before experiments. Male and female control ApoE -/-, SM22α-TRF2/ApoE -/-, or SM22α-TRF2 T188A /ApoE -/-mice were fed a high-fat diet (21% total fat, 0.2% cholesterol, and 0% sodium cholate) from 6 to 22 weeks, and blood and tissues were taken at euthanization.
Telomere Length and Telomere Fluorescence In Situ Hybridization Plaque Morphometry
Atherosclerotic plaque morphometry was determined as described previously 24 and in the online-only Data Supplement Methods section.
Lipid Measurements, Blood Counts, and Blood Pressure
Blood was taken from experimental animals every 4 weeks and serum lipids analyzed for total cholesterol, triglycerides, low-density lipoprotein, and high-density lipoprotein using a Dade-Behring Dimension autoanalyzer. Low-density lipoprotein was calculated using the Friedwald formula. Blood counts were analyzed on a Coulter counter and blood pressure determined by tail cuff.
Cytokine and Chemokine Detection Using FlowCytomix Assay
FlowCytomix assay (eBioscience, San Diego, CA) was used to determine chemokine (GM-CSF, MCP-1, MCP-3, MIP-1α, MIP-1β, RANTES, and CXCL1/KC) and cytokine (IL-6) concentrations in conditioned media from cell lines or mouse serum. Samples were analyzed according to the manufacturer's recommendations.
Statistical Analysis
Data that were normally distributed (eg, cultured cell foci and mouse plaque sizes) were compared using 1-way ANOVA (GraphPad Prism, GraphPad Software, Inc, La Jolla, CA) with no adjustments for multiple comparisons. Data that were not normally distributed were examined using Mann-Whitney U tests. Cumulative data (eg, cumulative cell proliferation) were examined by comparison of cell divisions at the end of the experiment using Mann-Whitney U tests. Data are expressed as mean±SEM or mean±SD. P<0.05 was considered statistically significant.
Results
TRF2 Is Reduced in Human Atherosclerotic Plaque VSMCs
Because human atherosclerotic plaque VSMCs show shortened telomeres and premature senescence, 7 we first examined expression of shelterin complex proteins in VSMCs cultured from normal human aorta or atherosclerotic plaques. Most proteins showed similar expression, but TRF2 was reduced in multiple plaque VSMC isolates ( Figure 1A ). TRF2 is regulated at both mRNA and protein levels. There was no difference in TRF2 mRNA expression between aortic (n=3) or plaque (n=3) VSMCs ( Figure 1C ) by quantitative polymerase chain reaction, despite the marked differences in TRF2 protein expression, suggesting posttranscriptional regulation of TRF2 protein. In some cells the stability of the TRF2 protein is regulated via ubiquitin-mediated proteasomal degradation, itself regulated by a p53-induced E3 ubiquitin ligase Siah-1a. 25 Consistent with previous studies, 26 p53 was increased in whole lysates of human plaques compared with normal vessels and also increased in smooth-muscle-actin (SMA)-positive cells in plaques compared with normal aorta ( Figure I in the online-only Data Supplement). p53 itself is also regulated by proteasomal degradation, suggesting that this mechanism may be active. Indeed, although p53 protein expression was undetectable in plaque and normal human VSMCs by Western blot (data not shown), expression of Siah-1a was increased 1.9-fold in plaque versus aortic VSMCs, associated with a 3.5-fold increased expression of the senescence marker p16 (n=3; Figure 1D ). To demonstrate whether p53 regulated TRF2 expression in VSMCs, we examined TRF2 levels in control or p53
-/-VSMCs after treatment with the proteasomal inhibitor MG132. Proteasomal inhibition decreased TRF2 expression in control VSMCs ( Figure 1E ), associated with increased p53 expression. TRF2 was increased in p53 -/-null VSMCs, consistent with a role for p53 in regulating TRF2 protein expression, but there was no significant effect of MG132 ( Figure 1E ).
We next examined whether reduced TRF2 expression in plaque VSMCs was associated with DNA damage. Cultured plaque VSMCs had reduced TRF2 nuclear foci, associated with increased foci of the DNA damage markers phosphorylated ATM (P-ATM) and γ-H2AX (Figure 2A and 2B) . Despite reduced TRF2 foci, plaque VSMCs showed increased colocalization of TRF2 foci with P-ATM and γ-H2AX, indicating DNA damage at telomeres, and colocalization of γ-H2AX with P-ATM (Figure 2A and 2B) . To confirm that TRF2 is also reduced in vivo and its association with DNA damage markers, we examined cells in normal aorta or advanced plaques (American Heart Association grade IV+). Cells expressing SMA in human plaques in vivo also showed reduced TRF2 and increased P-ATM and γ-H2AX expression ( Figure 2C and 2D). These findings suggest that TRF2 expression and binding to telomeres are reduced in plaque VSMCs, associated with increased DNA damage and DDR activation at telomeres. 
TRF2 Bypasses Senescence, Whereas TRF2188A Promotes VSMC Senescence
Reduced TRF2 in plaque VSMCs and the known role of TRF2 in protecting against senescence suggest that TRF2 may be a critical regulator of VSMC senescence. If correct, manipulation of TRF2 might be used to increase or decrease senescence in VSMCs in culture and in vivo to study the consequences of VSMC senescence on plaque development. TRF2 knockout is embryonally lethal in mice. 27 However, TRF2 contains different functional domains, including a C-terminal DNAbinding Myb domain that recognizes telomeric tandem repeat sequences at chromosome ends, a flexible hinge domain involved in protein-protein interactions, a TRF homology domain required for homodimerization, and a divergent N-terminal domain rich in basic residues (basic domain). Deletion of these regions both alone and together can promote senescence in transformed cells or those from newborns, both mouse and human, 11, 12 and thus act as a useful model for loss of TRF2 function. However, the effect of loss of TRF2 function varies widely between cell types (eg, see Reference 28 ), and the effect on VSMCs is not known, particularly for VSMCs from atherosclerosis models such as ApoE -/-mice. To find the most effective way of increasing or reducing TRF2 function in VSMCs, we stably expressed fulllength human TRF2 or truncations lacking the basic domain (ΔB), the Myb domain (ΔM), both (ΔB/ΔM), or TRF2 
TRF2 Promotes DNA Repair, Whereas TRF2188A Delays Repair
We next examined DNA repair after tert-butyl hydroperoxide (t-BHP), an oxidant that promotes premature senescence in VSMCs in part through induction of DSBs and telomere damage. 7 Because TRF2, TRF2 , again consistent with the known role of this residue in TRF2 phosphorylation ( Figure 3A) . T-BHP increased γ-H2AX expression in control cells and TRF2 T188A and TRF2 T188E VSMCs, but γ-H2AX expression was markedly reduced in TRF2 VSMCs. γ-H2AX returned to baseline by 16 hours in control and TRF2 T188E cells, but TRF2 T188A VSMCs maintained γ-H2AX expression to 16 hours, indicating long-term unrepaired damage ( Figure  3A) . Thus, TRF2 inhibits DNA damage (as seen by the lack of γ-H2AX expression at baseline and at any stage after DNA damage), and TRF2
T188A increases damage/inhibits repair (as seen by persistent γ-H2AX at 16 hours). TRF2 overexpression also reduced both γ-H2AX and P-ATM foci 1 hour after t-BHP ( Figure 3B through 3D ) and γ-H2AX foci in recovery ( Figure 3E ); in contrast, TRF2
T188A increased γ-H2AX foci 1 hour after t-BHP ( Figure 3C ), which persisted to >6 hours in recovery ( Figure 3E ). TRF2 T188E increased early γ-H2AX induction after t-BHP, but DNA damage normalized by 6 hours ( Figure 3E ).
DSBs can be quantified using an alkaline comet assay, with the kinetics of comet tail shortening reflecting efficiency of DSB repair. T-BHP-induced DSBs were repaired by 6 hours in control VSMCs, but TRF2 accelerated repair with recovery by 2 hours; TRF-2 T188E slowed initial DNA repair but was complete by 6 hours, whereas TRF2 T188A VSMCs showed markedly delayed repair to >6 hours ( Figure 3F and Figure III in the online-only Data Supplement). Thus, TRF2 overexpression inhibits replicative arrest in VSMCs, accelerates DSB repair after redox stress, and reduces DNA damage. TRF2
T188A/E induce premature replicative arrest, delay DNA repair, and increase DNA damage; these effects are most marked with TRF2
T188A and indicate that TRF2 and TRF2
T188A
can be used to examine the effects of prevention or induction of VSMC senescence, respectively. To determine the role of VSMC senescence in atherogenesis and plaque stability, we generated transgenic mice that expressed TRF2 or TRF2 T188A from the minimal SM22α promoter ( Figure IV in the online-only Data Supplement). The minimal SM22 promoter is expressed only in arterial VSMCs in adult mice and not in visceral smooth muscle cells, cardiomyocytes, or skeletal myocytes. 23 Three-base pair mutations were also introduced into the promoter CArG (CC(A/T)6GG-) boxes to prevent promoter downregulation when VSMCs undergo phenotypic modulation. 29 Recent studies have shown that bone marrow-derived myeloid cells can express VSMC markers in culture and atherosclerosis, 30 and vessel wallderived VSMCs can also express macrophage markers. 31 However, we have shown that this promoter is expressed in <1% of myeloid cells that express VSMC markers in atherosclerotic plaques in mice, 30 indicating that expression of transgenes from this promoter are specific for vessel wall-derived VSMCs.
Two founders from each line were studied, which each behaved similarly. SM22α-TRF2 and SM22α-TRF2 T188A mice were born with the expected frequencies, and the transgene was transmitted between generations and expressed only in arteries ( Figure 4A ). Although primary mouse VSMCs proliferate slower than mouse VSMC lines, VSMCs derived from SM22α-TRF2 mice showed the same features of increased proliferation ( Figure 4B ), reduced nondividing percentage ( Figure 4C ), and accelerated DSB repair ( Figure 4D ), which was particularly seen with normalization of comet lengths by 2 hours (Figure 4D) . Similarly, SM22α-TRF2 T188A VSMCs showed decreased proliferation, increased nondividing percentage, and defective initial DSB repair, indicating that transgene expression in these mice recapitulates expression of TRF2 and TRF2
188A in ApoE -/-VSMCs ( Figure II in the online-only Data Supplement). Importantly, apoptosis was similar in all cell types ( Figure 4C ), such that functional consequences of transgene expression in vivo were not attributed to increased/decreased VSMC apoptosis. SM22α-TRF2 and SM22α-TRF2 T188A mice showed no gross vascular or other abnormality, and γ-H2AX expression was similar in aortas of all of the mouse groups, indicating that this overall DNA damage was not affected; in contrast, the senescence marker p16 was markedly increased in SM22α-TRF2 T188A mice ( Figure 4E ), confirming that TRF2 T188A can induce markers of senescence in VSMCs in normal arteries in the absence of DNA damage.
The effect of TRF2 and TRF2 T188A on telomeres, telomere length, and chromosome structure in VSMCs from transgenic mice was examined using quantitative polymerase chain reaction for telomere length and telomere fluorescence in situ hybridization. Although TRF2 reduced telomere length, this was not associated with telomere deletions, and there was a trend toward reduced telomere fusions consistent with previous studies indicating a protective role for TRF2 overexpression. 8, 32 In contrast, TRF2 
Effects of TRF2 or TRF2 188A on Atherosclerosis
To examine the effect of VSMC senescence on atherosclerosis, SM22α-TRF2 and SM22α-TRF2 T188A mice were backcrossed with C57Bl6/J ApoE -/-mice, and male and female ApoE -/-, SM22α-TRF2/ApoE -/-, or SM22α-TRF2 T188A /ApoE -/-littermates were fat fed from 6 to 22 weeks. Body weight, blood pressure, serum lipids, total leukocyte counts, and differential leukocyte percentage showed no differences between groups (Figure VI in the online-only Data Supplement). However, both total atherosclerotic plaque and necrotic core areas were significantly increased in aortic root lesions of SM22α-TRF2 T188A mice ( Figures 5 and 6 and Table) . Plaque area was also increased in brachiocephalic arteries of SM22α-TRF2 In humans, rupture-prone plaques exhibit a thin fibrous cap and a relatively large necrotic core; we therefore undertook detailed analysis of plaque architecture in these mice. SM22α-TRF2 mice had significantly increased fibrous cap/plaque and cap/core ratios and reduced core/plaque ratios compared with control ApoE -/-mice ( Figure 6 and Table) , indicating a relative increase in fibrous cap and decrease in core areas. Overall, the percentage of SMApositive, mac3-positive, and apoptosis frequencies were similar between groups (Table) , although fibrous caps of SM22α-TRF2 mice showed more extensive SMA expression ( Figure 5 ). 
Mice Is Not Attributed to a Senescence-Associated Secretome
Premature senescence may promote atherogenesis by reducing the VSMC content of fibrous caps, a major factor in promoting plaque rupture and subsequent growth in humans. 33 However, senescence can also induce a senescence-associated secretome (SASP), a pattern of proinflammatory cytokines released when cells (including VSMCs) undergo replicative or stress-induced premature senescence 34 that might promote atherosclerosis by increasing monocyte invasion. However, both mac3-positive content of plaques (Table) and serum levels of SASP cytokines were similar (MCP-3, MCP-1, Mip-1β, and RANTES) or undetectable (Mip-1α, IL-1, and IL-6) in all of the mouse groups at 22 weeks ( Figure IX in the online-only Data Supplement).
To determine whether mouse VSMCs expressing TRF2 or TRF2 188A showed differences in SASP cytokine secretion, we cultured VSMCs expressing these proteins and determined cytokine secretion after 2 days. Conditioned media of ApoE -/-VSMCs expressing TRF2 or TRF2 T188A showed similar cytokine secretion to control cells (Figure X in the online-only Data Supplement). The increased atherosclerosis in SM22α-TRF2 T188A mice with a similar SASP profile in vivo and in culture thus suggests that VSMCs exert a direct protective effect on the vessel wall. 
Discussion
VSMC proliferation is a fundamental component of both historical and current models of atherogenesis. For example, the "response to injury" hypothesis viewed aberrant VSMC proliferation as a major primary event in plaque development. In contrast, more recent models suggest that VSMC proliferation is predominantly reparative, for example, as a response to inflammation. 35, 36 Although increased VSMC proliferation is seen in atherogenesis, VSMCs in advanced human plaques are characterized by multiple markers of senescence, including telomere loss, expression of the cyclin-dependent kinase inhibitors p21 and p16, and expression of senescence-associated β-galactosidase. 7 Although this indicates that VSMC senescence occurs in advanced plaques, it is not known whether senescence contributes to plaque development or the morphology of advanced lesions or its underlying mechanisms.
We demonstrate that human atherosclerotic plaque VSMCs show reduced TRF2 expression in vitro and markedly reduced binding of TRF2 to telomeres, associated with increased markers of DNA damage. Other shelterin proteins showed no consistently altered expression, suggesting that TRF2 is a critical regulator of VSMC senescence in atherosclerosis and that plaque VSMCs are very sensitive to telomere damage. TRF2 was also reduced and associated markers of DNA damage increased in α-SMA-positive cells in human plaques in vivo. TRF2 protein was regulated by proteasomal degradation that depended on p53. TRF2 reduced DNA damage, accelerated DSB repair, and inhibited replicative arrest in VSMCs, indicating that VSMC senescence may be attributed to both replicative exhaustion and stress-induced premature senescence. Using novel gain-and loss-of-function VSMCspecific expression of TRF2 or TRF2 T188A , we show that VSMC senescence promotes atherosclerosis and features of plaque vulnerability, including decreased relative fibrous cap and increased necrotic core areas, without a significant SASP.
We show that TRF2 is unique among the shelterin proteins in being downregulated in plaque VSMCs. TRF2 protein is regulated by ubiquitin-mediated degradation, in part by the p53-induced E3 ubiquitin ligase Siah-1. 25 VSMCs in plaques are characterized by multiple forms of DNA damage, including double-and single-strand breaks, oxidative lesions, and mtDNA damage 37, 38 ; DNA damage markers and activation of multiple DNA repair pathways are maintained in cultured plaque VSMCs. 7, 20, 38 Plaque VSMCs in culture and cells expressing α-SMA in human plaques showed downregulated TRF2 associated with markers of both DNA damage (γ-H2AX) and DNA repair (p-ATM). In culture, plaque VSMCs showed reduced TRF2 and increased Siah-1α, associated with increased p16. Although overall TRF2 expression was reduced after proteasomal inhibition, this was also associated with marked upregulation of p53, and the effect of proteasomal inhibition on TRF2 expression depended on p53. This suggests a specific mechanism for TRF2 downregulation in atherosclerosis by which DNA damage-induced activation of p53 and subsequently Siah-1α results in TRF2 degradation in plaque VSMCs.
Although studies on human plaque VSMCs do not indicate whether reduced TRF2 is a cause or consequence of senescence, we show that overexpression of TRF2 from a retrovirus promoter or from transgenic mice using the SM22α minimal promoter blocks cell senescence in culture. The latter is not a strong promoter, indicating that endogenous levels of TRF2 may be sufficient to prevent senescence. This hypothesis is strengthened by our studies using TRF2 188A , which induces senescence in VSMCs that express endogenous levels of wildtype TRF2. The use of both gain-and loss-of-function studies in vitro that show opposite effects strongly imply that TRF2 is a critical regulator of VSMC senescence and that the observed loss of TRF2 activity is a major factor in VSMC senescence in atherosclerosis.
To determine the effects of manipulating TRF2 in VSMCs in vivo on atherogenesis and plaque morphology directly we generated 2 novel transgenic mouse models that express VSMC-specific TRF2 or TRF2
188A as gain or loss of function, respectively. TRF2 and TRF2
188A were expressed at similar levels, a critical control to be able to compare their effects. TRF2 promoted proliferation, inhibited senescence, and accelerated DNA repair in VSMCs derived from SM22α-TRF2 mice, whereas TRF2
188A did the opposite. Furthermore, in normal aortas, TRF2
188A increased p16 expression with no change in γ-H2AX, indicating that TRF2
188A can promote VSMC senescence in the absence of widespread DNA damage. TRF2
188A promoted plaque development associated with increased plaque and necrotic core areas, whereas TRF2 expression increased the fibrous cap area relative to both plaque and core areas and reduced relative core size, with no change in apoptosis in either mouse group.
Recent genetic lineage tracing studies indicate that conventional markers of macrophages can also be expressed by cells derived from the vessel wall, 31 and markers of VSMCs can also be expressed by myeloid cells that differentiate in culture or migrate into the plaque. 30 This potentially might mean that myeloid cells activate VSMC promoters when they migrate into atherosclerotic plaques, confounding our interpretation that the effects that we observe are attributed to the effects of loss of TRF2 on vessel wall-derived VSMCs. However, we and others have shown that bone marrow-derived cells expressing SMC markers are either infrequent 30 or nonexistent 39 in plaques in ApoE mice and could not be demonstrated in fibrous caps of advanced plaques at 22 weeks. 30 We have also transplanted bone marrow-derived cells into ApoE -/-mice with transgenes expressed from the minimal SM22α promoter, which showed that <1% of cells in advanced plaques expressed the transgene and again there was no expression in fibrous caps. 30 Thus, the opposite effects of TRF2 and TRF2
188A expression on plaque morphology argue strongly that changes in TRF2 function in these transgenic mice are mediated through senescence of vessel wallderived VSMCs.
Premature senescence may promote atherogenesis by reducing the protective fibrous cap (as demonstrated here), via a SASP that might promote atherosclerosis by increasing monocyte invasion, or both. However, it has been difficult to demonstrate a functionally important SASP in mouse cells, and this often requires culture in physiological oxygen concentrations and extreme measures such as irradiation. 40 In addition, senescence induced by p16 (which is increased in SM22α-TRF2 T188A VSMCs and human plaque VSMCs) is often not associated with an SASP. 41 We find no differences in November 17, 2015
"classical" SASP cytokines in serum of transgenic mice compared with controls or in cultured VSMCs expressing TRF2 of TRF2
188A
. Although it is possible that a local SASP may influence cellular composition and morphology of plaques in vivo, other antiatherogenic effects of VSMCs should also be considered, including acting as a barrier to invasion of monocytes or prevention of plaque rupture that leads to plaque growth. In particular, our findings illustrate the profound protective properties of normal VSMC function on the vessel wall and a novel role of VSMC senescence in necrotic core formation. Our results may also explain why accelerated atherosclerosis and myocardial infarction are features of progeroid syndromes that show loss of VSMCs, DNA damage, and premature cellular senescence 42 and why genes that regulate senescence, such as the INK4/ARF locus, might be associated with heart attacks in genome-wide association studies. 43 Our data support a model of VSMC senescence in atherosclerosis involving telomere dysfunction, DNA damage, TRF2, and p53 ( Figure 7 ). In atherogenesis, mitogens from platelets, invading myeloid cells, and the local vessel wall promote VSMC replication. Inflammation and reactive oxygen species (for example) promote DNA damage, including in telomeres of replicating cells. DNA damage also activates p53, resulting in Siah-1-mediated degradation of TRF2, which causes exposure of telomere ends. The combination of replication, loss of TRF2 protection, and direct DNA damage induces telomere dysfunction. Telomere dysfunction results in activation of a DDR that further activates p53 and induction of p16. The p53 targets p21 and p16 induce senescence, in part mediated through hypophosphorylation of pRB.
In summary, we show that TRF2 is a major regulator of VSMC senescence and is downregulated in VSMCs from human atherosclerotic plaques. VSMC senescence promotes atherogenesis and necrotic core formation while reducing cap formation. Protection against VSMC senescence may represent a novel mechanism to reduce both plaque formation and features of vulnerable plaques. 
CLINICAL PERSPECTIVE
Proliferation of vascular smooth muscle cells (VSMCs) is a central axiom of both historical and current models of atherosclerosis, either as a response to injury or inflammation. The detrimental effect of VSMC proliferation has been endorsed by the success of antiproliferatives on drug-eluting stents, which have virtually eliminated in-stent stenosis. However, atherosclerosis is a disease of ageing, where proliferation of normal cells usually slows down. Indeed, human plaque VSMCs show premature senescence both in culture and in vivo, associated with telomere shortening and extensive DNA damage. Using human and mouse arteries, plaques and cells, and 2 novel transgenic mouse models, we show that human plaque VSMCs show reduced expression and telomere association of the key telomere protein TRF2. TRF2 reduces DNA damage, accelerates DNA repair, and protects VSMCs against senescence. In contrast, a TRF2 mutant (TRF2 T188A ) increases DNA damage, impairs DNA repair, and promotes VSMC senescence. TRF2
T188A increased atherosclerosis and necrotic core formation in apolipoprotein E -/-mice. In contrast, transgenic mice expressing TRF2 only in VSMCs show increased relative fibrous cap and reduced necrotic areas, promoting features of stable plaques. Our work indicates that VSMC senescence promotes plaque formation and has marked effects on the fibrous cap and necrotic core, directly promoting features of plaque vulnerability. In contrast to earlier views, our work indicates that VSMC proliferation may protect against atherogenesis, and senescence, not proliferation, might promote atherosclerosis and vulnerable plaques. The study also explains for the first time how specific progeroid diseases might be associated with atherosclerosis and premature heart attack.
SUPPLEMENTAL MATERIAL
Supplemental Methods
Protein Extraction, Western blotting
Protein extraction from cultured cells and Western blotting were performed as previously buffer. After addition of 40mM NaCl and formaldehyde, cross-linking was reversed at 65°C overnight. DNA was recovered using a mini-elute DNA purification kit (Qiagen). Telomere specific real-time PCR was performed as previously described 2 .
Immunocytochemistry
Immunocytochemistry for nuclear foci was performed as described previously 1 . Primary antibodies were rabbit anti-γ-H2AX ser139 , P-ATM, and TRF2 (#9718, #4526 and #2645, all 1:100, Cell Signaling Technologies). Secondary antibodies were Alexa Fluro488 goat antimouse IgG and Alexa Fluro694 Goat anti-rabbit IgG (1:500; Invitrogen). γ-H2AX ser139 foci intensity was assayed using ImageJ (NIH)
Immunohistochemistry
Immunohistochemistry of human and mouse arteries was performed as described previously 3 .
Cell Culture
Mouse cell lines were cultured in DMEM supplemented with 10U/ml Penicillin (Sigma), 10µg/ml Streptomycin (Sigma), 5µg/ml L-Glutamine (Sigma), 10% fetal calf serum (Sigma) ± hygromycin. Cells were treated with t-butyl hydroperoxide (t-BHP, 100µM) for 1 hour at 80% confluency prior to analysis at selected time points.
Measurement of Telomere Length (Q-PCR)
The length of mouse telomeres was measured by Q-PCR on a Rotor-Gene (Corbett final volume. The reaction mix for telomere length was similar to 36B4, except using 300nM of both forward and reverse primers. qPCR reaction conditions were 95°C for 15 minutes, followed by 35 cycles of elongation steps starting at 95°C for 15 seconds, 54°C for 60 seconds and 72°C for 30 seconds, and finished at 72°C for 10 minutes. ApoE -/-mouse DNA, serially diluted from 60ng to 1.875ng, was used to generate a reaction standard curve. Each DNA sample was run in triplicate and two negative controls (no template DNA; no primers)
were run in duplicate in parallel. The input amounts of telomere and 36B4 DNA were calculated based on the standard curve generated after averaging the threshold cycle number (Ct) values for each sample. The average telomere length ratio (ATLR) was then calculated by dividing the amount of telomeric DNA to the amount of 36B4 product.
Chromosome harvest and and telomere FISH
To prepare metaphase chromosomes, mouse VSMCs were treated with 0.03µg/mL of 
Analysis of Atherosclerosis
Atherosclerosis extent and composition was analyzed as described previously 4 Briefly, sections from the aortic root and brachiocephalic arteries were stained with H&E, α-SMA, 
